- Home
- CLPT vs CTNM Comparison
CLPT vs CTNM Comparison
Compare CLPT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPT
- CTNM
- Stock Information
- Founded
- CLPT 1998
- CTNM 2009
- Country
- CLPT United States
- CTNM United States
- Employees
- CLPT N/A
- CTNM N/A
- Industry
- CLPT Medical/Dental Instruments
- CTNM
- Sector
- CLPT Health Care
- CTNM
- Exchange
- CLPT Nasdaq
- CTNM Nasdaq
- Market Cap
- CLPT 299.3M
- CTNM 248.7M
- IPO Year
- CLPT N/A
- CTNM 2024
- Fundamental
- Price
- CLPT $10.65
- CTNM $11.88
- Analyst Decision
- CLPT Strong Buy
- CTNM Strong Buy
- Analyst Count
- CLPT 3
- CTNM 4
- Target Price
- CLPT $27.67
- CTNM $22.75
- AVG Volume (30 Days)
- CLPT 276.2K
- CTNM 277.7K
- Earning Date
- CLPT 11-06-2025
- CTNM 11-05-2025
- Dividend Yield
- CLPT N/A
- CTNM N/A
- EPS Growth
- CLPT N/A
- CTNM N/A
- EPS
- CLPT N/A
- CTNM N/A
- Revenue
- CLPT $33,593,000.00
- CTNM N/A
- Revenue This Year
- CLPT $22.34
- CTNM N/A
- Revenue Next Year
- CLPT $25.50
- CTNM N/A
- P/E Ratio
- CLPT N/A
- CTNM N/A
- Revenue Growth
- CLPT 19.68
- CTNM N/A
- 52 Week Low
- CLPT $9.76
- CTNM $3.35
- 52 Week High
- CLPT $19.22
- CTNM $20.30
- Technical
- Relative Strength Index (RSI)
- CLPT 48.20
- CTNM 66.66
- Support Level
- CLPT $10.33
- CTNM $11.32
- Resistance Level
- CLPT $11.45
- CTNM $13.09
- Average True Range (ATR)
- CLPT 0.51
- CTNM 1.02
- MACD
- CLPT 0.01
- CTNM -0.04
- Stochastic Oscillator
- CLPT 41.55
- CTNM 64.93
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.